US 11344513
Dosage forms and methods for enantiomerically enriched or pure bupropion
granted A61KA61K31/137A61P
Quick answer
US patent 11344513 (Dosage forms and methods for enantiomerically enriched or pure bupropion) held by AXSOME THERAPEUTICS, INC. expires Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- AXSOME THERAPEUTICS, INC.
- Grant date
- Tue May 31 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon May 26 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 17
- CPC classes
- A61K, A61K31/137, A61P, A61P25/28